ORIGINAL PAPERS

   BREAST CANCER

Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?

Danny Robson, Sunil Verma
The Oncologist 2009; 14: 950-958; doi:10.1634/theoncologist.2008-0070
[Abstract] [Full Text] [PDF]  

SUMMARY: The article reviews the literature reporting the efficacy and toxicity of adjuvant anthracycline (doxorubicin and epirubicin) therapy for early-stage invasive breast cancer and summarizes the progress toward molecular predictive markers of anthracycline efficacy. The newer nonanthracycline regimens and their relative merits are also discussed.

Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?

Kathleen I. Pritchard
The Oncologist 2009; 14: 959-962; doi:10.1634/theoncologist.2009-0219
[Full Text] [PDF]  

SUMMARY: The author argues for the view that the clinical role of the anthracyclines will persist in the adjuvant therapy of breast cancer for some time to come.

NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial

Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Erin Green, Hanna K. Sanoff, Howard McLeod, Jan Buckner
The Oncologist 2009; 14: 970-978; doi:10.1634/theoncologist.2009-0175
[Abstract] [Full Text] [PDF]  

SUMMARY: This review summarizes the history and major findings of the N9741 clinical trial in patients with metastatic colorectal cancer, which has helped to change the standard of care for this disease in the U.S. and worldwide.

Plasma Fibrinogen Levels and Prognosis in Patients with Ovarian Cancer: A Multicenter Study

Stephan Polterauer, Christoph Grimm, Veronika Seebacher, Nicole Concin, Christian Marth, Caroline Tomovski, Heinrich Husslein, Heinz Leipold, Katrin Hefler-Frischmuth, Clemens Tempfer, Alexander Reinthaller, Lukas Hefler
The Oncologist 2009; 14: 979-985; doi:10.1634/theoncologist.2009-0079
[Abstract] [Full Text] [PDF]  

SUMMARY: This study evaluated the prognostic value of pretherapeutic plasma fibrinogen levels in a large multicenter series of patients with epithelial ovarian cancer. Elevated plasma fibrinogen levels were significantly associated with advanced tumor stage and the presence of a postoperative residual tumor mass, but not with histological grade and type. Higher plasma fibrinogen levels were associated with impaired disease-free and overall survival.

Prognostic Factors in Metastatic Melanoma Patients Treated with Biochemotherapy and Maintenance Immunotherapy

David R. Minor, Dan Moore, Christine Kim, Mohammed Kashani-Sabet, Suraj S. Venna, Wei Wang, Peter Boasberg, Steven O'Day
The Oncologist 2009; 14: 995-1002; doi:10.1634/theoncologist.2009-0083
[Abstract] [Full Text] [PDF]  

SUMMARY: This study examines prognostic factors in metastatic melanoma patients treated with biochemotherapy to determine which patients might benefit from this intensive therapy. Results suggest that patients who have either a normal lactate dehydrogenase level or skin or nodes as one of their metastatic sites may have durable remissions with this therapy.

Should Patients with High-Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy?

Scott M. Schuetze, Shreyaskumar Patel
The Oncologist 2009; 14: 1003-1012; doi:10.1634/theoncologist.2009-0007
[Abstract] [Full Text] [PDF]  

SUMMARY: The authors argue in favor of the use of chemotherapy in the management of high-risk, localized, soft tissue sarcoma.

Adjuvant Chemotherapy in Localized Soft Tissue Sarcomas: Still Not Proven

Jean-Yves Blay, Axel Le Cesne
The Oncologist 2009; 14: 1013-1020; doi:10.1634/theoncologist.2009-0126
[Abstract] [Full Text] [PDF]  

SUMMARY: The authors argue that adjuvant chemotherapy has not been proven to improve outcome in soft tissue sarcoma patients.

Contemporary Imaging in Sarcoma

Jonathan Landa, Lawrence H. Schwartz
The Oncologist 2009; 14: 1021-1038; doi:10.1634/theoncologist.2009-0194
[Abstract] [Full Text] [PDF]  

SUMMARY: This article discusses various imaging techniques used in the evaluation of both bone and soft tissue sarcomas.

The Assessment and Management of Delirium in Cancer Patients

Shirley H. Bush, Eduardo Bruera
The Oncologist 2009; 14: 1039-1049; doi:10.1634/theoncologist.2009-0122
[Abstract] [Full Text] [PDF]  

SUMMARY: Outlined are the causes of delirium in advanced cancer, especially drug-induced delirium, and the diagnosis and management of opioid-induced neurotoxicity.

Prognostic Significance of Epidermal Growth Factor Receptor Phosphorylation and Mutation in Head and Neck Squamous Cell Carcinoma

Takanori Hama, Yuki Yuza, Yoshimichi Saito, Jin O-uchi, Shu Kondo, Masataka Okabe, Hisashi Yamada, Takakuni Kato, Hiroshi Moriyama, Satoshi Kurihara, Mitsuyoshi Urashima
The Oncologist 2009; 14: 1050; doi:10.1634/theoncologist.2009-0058erratum
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.